Tech Company Financing Transactions
Cybrexa Therapeutics Funding Round
Connecticut Innovations, HighCape Partners and private investors joined a $6 million Series B venture round for Cybrexa Therapeutics. The financing round was announced on 6/16/2017.
Transaction Overview
Company Name
Announced On
6/16/2017
Transaction Type
Venture Equity
Amount
$6,000,000
Round
Series B
Proceeds Purpose
The Series B funding will enable Cybrexa to complete the build-out of its facilities and continue the development its tumor-localizing DNA repair inhibitors, which they refer to as Tumor Specific Drugs (TSDs).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
395 Winchester Ave. 5 Science Park
New Haven, CT 06511
USA
New Haven, CT 06511
USA
Phone
Website
Email Address
Not Recorded
Overview
Cybrexa is a privately funded biotechnology company dedicated to developing an entirely new class of small molecule DNA repair inhibitors (TSDs) that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Kevin Didden
Chief Executive Officer
Per Hellsund
Chief Medical Officer
Arthur DeCillis
Chief Medical Officer
Peter Glazer
Chief Scientific Officer
Vishwas Paralkar
Co-Founder
Ranjit Bindra
Browse more venture capital transactions:
Prev: 6/16/2017: Lua Technologies venture capital transaction
Next: 6/16/2017: Ridibooks venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs